Skip to main content
Figure 1 | Journal of Experimental & Clinical Cancer Research

Figure 1

From: AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models

Figure 1

IBC xenografted tumors express low HER2 and low to medium HER3 levels. A. Total HER2, B. Total HER3, C. HER2-HER3 heterodimers, and D, HER3-PI3K complexes were measured in two xenografted tumor samples from each SUM149 or FC-IBC-02 cell lines by VeraTag™ technology. Normalized relative expression levels were compared with indicated breast cancer cell lines.

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us